Highlights ClouDr Group Limited

Equities

9955

KYG2216H1011

Delayed Hong Kong S.E. Other stock markets 02:46:46 2024-06-07 EDT			5-day change	1st Jan Change
2.47 ^HKD	0.00%		-7.87%	-64.09%

06-06	ClouDr Group Limited Announces Resignation of Director and Change in Composition of Audit Committee	CI
06-05	China Accepts Marketing Application for ClouDr Unit's Vitamin B6 Injection	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

China Accepts Marketing Application for ClouDr Unit's Vitamin B6 Injection	06-04	MT
ClouDr Group Limited Announces Application for Market Launch of Vitamin B6 Injection Solution	06-04	CI
ClouDr Launches Digital Employee to Improve Online-to-Offline Operation Services	04-15	MT
ClouDr Group's Net Loss Shrinks 81% in 2023 as Revenue Rises 23.5%	03-22	MT
ClouDr Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	03-21	CI
ClouDr Group Limited Announces Launch of Proprietary Product, Hetangjin Dapagliflozin Tablets	03-10	CI
ClouDr Group Limited Enters into A Non-Legally Binding Strategic Cooperation Agreement with China Resources Kunming Shenghuo Pharmaceutical Co., Ltd	03-05	CI
ClouDr Buys Back Shares	01-25	MT
ClouDr Group Trustee Buys 1.3 Million Shares Under Award Scheme	01-17	MT
ClouDr Unit to Get 200 Million Yuan Capital Injection	01-12	MT
ClouDr Buys Back Shares for Incentive Scheme	01-11	MT
ClouDr Group Applies to Register Diabetes Digital Therapeutics in China	01-03	MT
ClouDr Group Limited Completes the Application for Registration as A Medical Device in the People's Republic of China in Respect of ClouDT-01	01-03	CI
ClouDr Group to Buy Up to HK$80 Million of Shares	12-28	MT
ClouDr Signs Marketing Deal With Shanxi Jinbo Bio Pharmaceutical	12-28	MT
ClouDr Group Limited Enters into a Non-Legally Binding Strategic Cooperation Agreement with Shanxi Jinbo Bio-Pharmaceutical Co., Ltd	12-27	CI
ClouDr Group Signs Digital Marketing Agreement with Pharmaceutical Company	11-29	MT
ClouDr Group Limited Announces New Efficacy of Ischelium on Brain Covidative Fund Approval	11-15	CI
ClouDr Group Chairman/CEO Boosts Shareholding	23-10-31	MT
ClouDr Group to Partner with Hong Kong Magicure to Facilitate Cross-Border Access to Drugs in China	23-09-07	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights ClouDr Group Limited

Equities

9955

KYG2216H1011

Highlights

Filters